Study of Ruxolitinib in Colorectal Cancer Patients
Public ClinicalTrials.gov record NCT02119676. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to determine if ruxolitinib, in combination with regorafenib, is safe and effective in the treatment of metastatic colorectal cancer.
Study identification
- NCT ID
- NCT02119676
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 396 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2014 (Type not available)
- Primary completion
- Feb 2016 (Actual)
- Completion
- Dec 2016 (Actual)
- Last update posted
- Feb 13, 2018
2014 – 2016
United States locations
- U.S. sites
- 57
- U.S. states
- 21
- U.S. cities
- 57
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Chandler | Arizona | — | — |
| Not listed | Gilbert | Arizona | — | — |
| Not listed | Mesa | Arizona | — | — |
| Not listed | Scottsdale | Arizona | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Pasadena | California | — | — |
| Not listed | Santa Barbara | California | — | — |
| Not listed | Aurora | Colorado | — | — |
| Not listed | Colorado Springs | Colorado | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Altamonte Springs | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Ocala | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Niles | Illinois | — | — |
| Not listed | Lafayette | Indiana | — | — |
| Not listed | Ames | Iowa | — | — |
| Not listed | New Orleans | Louisiana | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Jefferson City | Missouri | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Lincoln | Nebraska | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Henderson | Nevada | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | Albany | New York | — | — |
| Not listed | Binghamton | New York | — | — |
| Not listed | Hudson | New York | — | — |
| Not listed | Johnson City | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | The Bronx | New York | — | — |
| Not listed | Canton | Ohio | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Easley | South Carolina | — | — |
| Not listed | Greenville | South Carolina | — | — |
| Not listed | Greer | South Carolina | — | — |
| Not listed | Sumter | South Carolina | — | — |
| Not listed | Chattanooga | Tennessee | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Arlington | Texas | — | — |
| Not listed | El Paso | Texas | — | — |
| Not listed | Fort Worth | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Paris | Texas | — | — |
| Not listed | Plano | Texas | — | — |
| Not listed | Tyler | Texas | — | — |
| Not listed | American Fork | Utah | — | — |
| Not listed | Bountiful | Utah | — | — |
| Not listed | Murray | Utah | — | — |
| Not listed | Provo | Utah | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | West Jordan | Utah | — | — |
| Not listed | Roanoke | Virginia | — | — |
| Not listed | Vancouver | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02119676, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 13, 2018 · Synced Nov 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02119676 live on ClinicalTrials.gov.